Skip to main content
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • CEBP Focus Archive
    • Meeting Abstracts
    • Collections
      • Disparities Collection
      • Editors' Picks
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • OnlineFirst
    • Editors' Picks
    • Citation
    • Author/Keyword
  • News
    • Cancer Discovery News
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Cancer Epidemiology, Biomarkers & Prevention
Cancer Epidemiology, Biomarkers & Prevention

Advanced Search

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • CEBP Focus Archive
    • Meeting Abstracts
    • Collections
      • Disparities Collection
      • Editors' Picks
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • OnlineFirst
    • Editors' Picks
    • Citation
    • Author/Keyword
  • News
    • Cancer Discovery News
Letters to the Editor

Cyclin E Overexpression Relates to Ovarian Cancer Histology but not to Risk Factors

Joellen M. Schildraut, Patricia G. Moorman, Brian Calingaert and Andrew Berchuck
Joellen M. Schildraut
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Patricia G. Moorman
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Brian Calingaert
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Andrew Berchuck
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1158/1055-9965.EPI-08-0491 Published July 2008
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

In Response: We appreciate the opportunity to respond to the concerns raised by Dr. Risch related to our recent publication about the relationship between cyclin E overexpression and epidemiologic risk factors in ovarian cancer (1). The first concern was with the statistical significance of the difference in the number of lifetime ovulatory cycles among the cyclin E–positive and cyclin E–negative ovarian cancer cases. Dr. Risch suggested that we use a 2-degree-of-freedom test to evaluate the significance of this relationship. The second concern related to the inclusion of mucinous cases, which Dr. Risch believes are not associated with reproductive risk factors such as ovulation and oral contraceptive use that predispose to other histologic types of ovarian cancer.

In response to these concerns, we provide Table 1 below, which shows the case-case analysis of lifetime ovulatory cycle tertiles previously reported in Table 4 of the article, but now without mucinous cases. We have also included the P values from the 2-degree-of-freedom test. Removing the 60 (7 cyclin E positive and 53 cyclin E negative) mucinous cases results in the point estimates becoming somewhat stronger, and the P values show strong statistical significance. Addressing the second concern, we repeated the analysis in Table 3 of our article omitting mucinous cancers, and the results were virtually identical to our original findings. These results are given in Table 2 . The point estimate for the relationship between lifetime ovulatory cycles among cyclin E–positive cases compared with controls remained the same as in the original analysis [odds ratio, 1.18; 95% confidence interval (95% CI), 1.07–1.30], whereas the point estimate for the association between lifetime ovulatory cycles and the cyclin E–negative cases compared with controls changed slightly from 1.05 (95% CI, 0.98–1.14) to 1.06 (95% CI, 0.97-1.15). The odds ratios and 95% CIs for the relationship between the number of years pregnant and years of oral contraceptive use in the analysis of cyclin E–positive cases and cyclin E–negative cases compared with controls are also similar to the original analyses that included the mucinous cases.

View this table:
  • View inline
  • View popup
Table 1.

Case-case analysis shown in Table 4 of original article but omitting mucinous cancers

View this table:
  • View inline
  • View popup
Table 2.

Case-control analyses derived from Table 3 of original article but omitting mucinous cancers

We also want to point out that the P value of 0.11 derived by Dr. Risch for the relationship between oral contraceptive use and cyclin E–positive and cyclin E–negative cases clearly cannot be correct because the 95% confidence limits do not even overlap (Table 3). We do not know how Dr. Risch came up with what he calls a “rough estimate” P value, but when we conducted a case-only analysis of this relationship we found a P value of 0.0004. In a similar analysis of the number of lifetime ovulatory cycles in positive cases compared with negative cases, we calculated a P value of 0.003. In doing this reanalysis, we noticed that in the footnote to Table 3 we incorrectly reported that the sample size of cyclin E–negative cases was 166, when in fact the sample size is 299. This may explain the discrepancy between Dr. Risch's rough estimate P value being >0.05 and the fact that the confidence intervals do not overlap.

We appreciate Dr. Risch's thoughtful comments and the opportunity to provide further analyses, which address these issues.

Disclosure of Potential Conflicts of Interest

No potential conflicts of interest were disclosed.

References

  1. ↵
    Schildkraut JM, Moorman PG, Bland AE, et al. Cyclin E overexpression in epithelial ovarian cancer characterizes an etiologic subgroup. Cancer Epidemiol Biomarkers Prev 2008;17:585–93.
    OpenUrlAbstract/FREE Full Text
PreviousNext
Back to top
Cancer Epidemiology Biomarkers & Prevention: 17 (7)
July 2008
Volume 17, Issue 7
  • Table of Contents
  • Table of Contents (PDF)

Sign up for alerts

View this article with LENS

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Cancer Epidemiology, Biomarkers & Prevention article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Cyclin E Overexpression Relates to Ovarian Cancer Histology but not to Risk Factors
(Your Name) has forwarded a page to you from Cancer Epidemiology, Biomarkers & Prevention
(Your Name) thought you would be interested in this article in Cancer Epidemiology, Biomarkers & Prevention.
Citation Tools
Cyclin E Overexpression Relates to Ovarian Cancer Histology but not to Risk Factors
Joellen M. Schildraut, Patricia G. Moorman, Brian Calingaert and Andrew Berchuck
Cancer Epidemiol Biomarkers Prev July 1 2008 (17) (7) 1841-1842; DOI: 10.1158/1055-9965.EPI-08-0491

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Cyclin E Overexpression Relates to Ovarian Cancer Histology but not to Risk Factors
Joellen M. Schildraut, Patricia G. Moorman, Brian Calingaert and Andrew Berchuck
Cancer Epidemiol Biomarkers Prev July 1 2008 (17) (7) 1841-1842; DOI: 10.1158/1055-9965.EPI-08-0491
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Disclosure of Potential Conflicts of Interest
    • References
  • Figures & Data
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

  • Shift Work, Chronotype, and Cancer Risk—Response
  • Shift Work, Chronotype, and Cancer Risk—Letter
  • Night Shift Work Increases Cancer Risk of Women—Letter
Show more Letters to the Editor
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook   Twitter   LinkedIn   YouTube   RSS

Articles

  • Online First
  • Current Issue
  • Past Issues

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians
  • Reviewers

About Cancer Epidemiology, Biomarkers & Prevention

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2019 by the American Association for Cancer Research.

Cancer Epidemiology, Biomarkers & Prevention
eISSN: 1538-7755
ISSN: 1055-9965

Advertisement